Adipokines have emerged as central mediators of insulin sensitivity and metabolism, in part due to the known association of obesity with metabolic syndrome disorders such as type 2 diabetes. Recent studies in rodents have identified the novel adipokine vaspin as playing a protective role in inflammatory metabolic diseases by functioning as a promoter of insulin sensitivity during metabolic stress. However, at present the skeletal muscle and adipose tissue expression of vaspin in humans is poorly characterised. Furthermore, the functional role of vaspin in skeletal muscle insulin sensitivity has not been studied. Since skeletal muscle is the major tissue for insulin-stimulated glucose uptake, understanding the functional role of vaspin in human muscle insulin signalling is critical in determining its role in glucose homeostasis. The objective of this study was to profile the skeletal muscle and subcutaneous adipose tissue expression of vaspin in humans of varying adiposity, and to determine the functional role of vaspin in mediating insulin signalling and glucose uptake in human skeletal muscle. Our data shows that vaspin is secreted from both human subcutaneous adipose tissue and skeletal muscle, and is more highly expressed in obese older individuals compared to lean older individuals. Furthermore, we demonstrate that vaspin induces activation of the PI3K/AKT axis, independent of insulin receptor activation, promotes GLUT4 expression and translocation and sensitises older obese human skeletal muscle to insulin-mediated glucose uptake.
Introduction
The recognition that adipose tissue is an endocrine organ, capable of secreting a plethora of adipose-secreted cytokines (adipokines) that mediate tissue crosstalk, has transformed our understanding of metabolism, with implications for the treatment of metabolic diseases such as type 2 diabetes (Bluher 2014 , Bluher & Mantzoros 2015 . It has long been established that the accumulation of abdominal fat (central adiposity) is associated with insulin resistance (Pratley et al. 1995 , Carey et al. 1996 , Kahn & Flier 2000 and it is now known that in obese individuals the adipose tissue becomes inflamed, with infiltratedpro-inflammatory and anti-inflammatory adipokines from adipocytes (Tilg & Moschen 2006 . In this regard, several studies have profiled adipokine expression and secretion in visceral adipose tissue (VAT) and recent proteomic analysis of adipose tissue secretome has identified over 600 adipokines (Lehr et al. 2012) . In addition, adipokines are also secreted from subcutaneous adipose tissue (SAT) (Skurk et al. 2007 , Blaber et al. 2012 , Pellegrinelli et al. 2015 . Considering that SAT represents a large proportion of total adipose tissue (Rossi et al. 2011 , Rosqvist et al. 2017 , SAT-derived adipokines are likely important contributors to tissue crosstalk and systemic inflammatory burden.
The functional role of the adipokines, leptin and adiponectin, as mediators of metabolic health and insulin sensitivity are well described. However, at present the functional role of many novel adipokines in regulating human insulin sensitivity and glucose handling is poorly understood (Nicholson et al. 2018) . Partly this is because despite skeletal muscle being the major organ for insulin-stimulated glucose uptake (Thiebaud et al. 1982) , the expression and functional role of these adipokines in human skeletal muscle has not been studied (Nicholson et al. 2018) . Given that age is a risk factor for the onset of type 2 diabetes (Kalyani et al. 2017) , understanding the effect of these different adipokines on skeletal muscle insulin sensitivity, particularly in older individuals, is important in determining the potential to target them therapeutically. Of the recently identified novel adipokines, one of the most interesting is vaspin (SERPINA12), a 47 kDa protein, which was first reported in the VAT of the genetically obese OLETF rat (Hida et al. 2000) . Importantly, several different animal models have recently implicated vaspin as an adipokine that functions to promote insulin sensitivity during metabolic stress. In a diabetic mouse model, administration of recombinant vaspin increased insulin sensitivity and glucose tolerance, whilst reducing the expression of pro-inflammatory adipokines including TNF-α and resistin and increasing the expression of adiponectin (Hida et al. 2000) . Similar increases in insulin sensitivity have been reported in both db/db and C57BL6 mice following administration with recombinant vaspin (Heiker et al. 2013) , whilst transgenic mice overexpressing vaspin display improved glucose tolerance and are protected from obesity when challenged with a high-fat diet .
Currently, very little is known with regard to the expression and secretory profile of vaspin in humans, or its functional role in human skeletal muscle tissue. However, serum concentrations of vaspin have been reported to be associated with insulin resistance in both non-diabetic and type 2 diabetic patient cohorts (Youn et al. 2008 , Aust et al. 2009 , Jian et al. 2014 , and its expression has been detected in the SAT of obese but not lean individuals (Kloting et al. 2006) , supporting the notion that vaspin is a key adipokine in mediating metabolic health and insulin sensitivity (Jian et al. 2014) . Therefore, the aim of this study was to examine the expression of vaspin in human skeletal muscle and SAT in elderly individuals of varying adiposity, and to determine the functional effect of recombinant human vaspin on insulin signalling and glucose uptake in human skeletal muscle tissue.
Materials and methods

Human samples
Gluteus maximus skeletal muscle, SAT and blood samples were obtained from 21 lean (BMI 22.8 ± 0.3, age 71 ± 1.6 years) and 17 obese (BMI 34.5 ± 0.9, age 66 ± 2 years) elderly age-matched individuals undergoing elective hip-replacement surgery at the Royal Orthopaedic Hospital, Birmingham, UK, and Russells Hall Hospital, Dudley, UK. Diabetic patients and those taking antiinflammatory medication within 2 weeks prior to surgery were excluded from the study. Skeletal muscle biopsies were also collected from n = 7 young lean individuals. Informed consent was obtained from all patients prior to sample collection and full ethical approval for the study was obtained from the Research Ethics Committee (NRES 13/NE/0222) in line with the Declaration of Helsinki.
Sample collection, processing, storage and subsequent experimental procedures were carried out in compliance with Human Tissue Authority guidelines under the Human Tissue Act (2004). Serum was obtained from blood samples (5 mL) taken at the time of surgery by allowing them to clot at room temperature for 20-30 min, followed by centrifugation at 1620 g for 10 min. Patient characteristics are detailed in Table 1 .
Isolation of primary human myoblasts and their differentiation into myotubes
Skeletal muscle samples (~200 mg) were sliced with a scalpel, placed in 5 mL of 0.05% trypsin-EDTA solution and rotated in an incubator (37°C, 5% CO 2 ) for 15 min. Trypsin was inactivated by the addition 5 mL of myoblast growth media (Ham's F10 nutrient mix, supplemented with 20% HyClone research-grade foetal bovine serum and 1% penicillin and streptomycin). The solution was centrifuged for 5 min at 2000 g and the resulting pellet re-suspended in 12 mL of myoblast growth medium before transfer to an uncoated T75 cell culture flask for 20 min. Finally, the solution was transferred to a T75 cell culture flask precoated with 0.2% gelatine. Myoblast growth medium was replaced every 48 h.
For experimentation, myoblasts were grown to confluence (5-7 days) and differentiation into myotubes was induced by replacing myoblast growth media with differentiation media (Ham's F10 nutrient mix (Sigma-Aldrich), supplemented with 6% horse serum (Sigma-Aldrich) and 1% penicillin and streptomycin. Differentiation media was replaced every second day. All experiments were conducted on the 8th day of differentiation. Myotubes were immunostained (Fig. 3A ) for desmin as previously described (O'Leary et al. 2017 ).
Generation of adipose and muscle-conditioned media
SAT or skeletal muscle derived from lean and obese subjects was incubated at 37°C, 5% CO 2 in serum-free culture media (Ham's F10 nutrient mix, Sigma-Aldrich) at a ratio of 1 g:10 mL for up to 24 h. In the case of adipose tissue, larger samples were divided into segments of ~1 g to ensure that the surface area of adipose tissue exposed to medium remained approximately constant. For time course analysis of secreted vaspin, 50 µL aliquots of conditioned media were taken hourly for 6 h and then again at 24 h. Supernatants were removed and stored at −80°C for western blot analysis.
RNA extraction and gene expression analysis
Snap-frozen skeletal muscle and SAT samples (~100 mg) were first ground into a fine powder using a pestle and mortar under liquid nitrogen. Powdered tissue was immediately transferred to 1 mL of TRIzol reagent (Invitrogen) and homogenised using a Qiagen Tissue Ruptor (Qiagen). Primary human myotubes were lysed in 1 mL of TRIzol reagent (Life Technologies).
RNA was extracted as described in the manufacturer's protocol. RNA was re-suspended in 30 µL of RNasefree water (Life Technologies) and heated at 55°C for 10 min. RNA was quantified using a NanoDrop 2000 (Life Technologies). Relative mRNA expression was determined by Quantitative Real-Time Polymerase Chain (qRT-PCR), performed using PrecisionTM OneStepPLUS qRT-PCR (with SYBR-green) mastermix (Primerdesign, UK), 5 ng total RNA and primers as described in Supplementary Table 1 (see section on supplementary data given at the end of this article). All reactions were performed using a BioiRd sfx cycler (Bio-Rad).
Immunoblotting analysis
Aliquots of powdered skeletal muscle tissue, SAT and primary human myotubes were lysed in RIPA buffer (Life Technologies) containing Phosphatase Inhibitor Cocktail 3 (1:100, Sigma-Aldrich) and Protease Inhibitor Cocktail (1:100, Sigma-Aldrich). After addition of RIPA buffer, samples were placed on ice for 20 min. Total protein in cell and tissue lysates was quantified by performing a BCA assay (Life Technologies) and protein samples prepared for gel electrophoresis by diluting in loading buffer consisting of 2-mercaptoethanol (Sigma-Aldrich), 4× Laemmli sample buffer and double distilled H 2 O, followed by boiling for 10 min in a heat block. For adipose and muscle-conditioned media samples, 10 µL of conditioned media diluted in loading buffer was loaded per sample. For cell lysates, 10-15 µg of protein was loaded per sample depending on the particular western blot.
Samples were loaded into a 5% stacking gel and separated by performing 12% SDS-PAGE. Protein was transferred to a methanol-activated PVDF membrane Membranes were immuno-probed overnight at 4°C, with primary antibodies as described in Supplementary Table 2, followed by incubation for 2 h at RT with the appropriate secondary antibody (HRP-linked anti-rabbit/ anti-mouse IgG secondary antibody (1:10,000; GE Healthcare)). Blots were developed using Amersham ECL Prime (GE Healthcare), and imaged using a ChemiDoc MP System (Bio-Rad) (Supplementary Figs 1, 2, 3 and 4). Densitometry analysis of bands was performed using an open-source, public domain software package (ImageJ v1.47).
Vaspin ELISA
Serum vaspin was measured using a commercially available human vaspin ELISA kit (AdipoGen Life Sciences), following the manufactures instructions. Serum samples were diluted 1:4 in ELISA buffer and the plate was read on a BioTek EL808 microtiter plate reader (BioTek, Swindon, UK).
MesoScale immunoassays
Myotubes were cultured in 96-well plates and stimulated with 10 nM human insulin (I0908, Sigma-Aldrich), 100 ng/mL of recombinant human vaspin (R&D Systems) or 100 ng/mL recombinant human vaspin immediately followed by 10 nM insulin. Cells were lysed in 90 µL MSD lysis buffer (MesoScale Discovery, Gaithersburg, Massachusetts, USA) containing Phosphatase Inhibitor Cocktail 3 (1:100 dilution, Sigma-Aldrich) and a Protease Inhibitor Cocktail (1:100 dilution, Sigma-Aldrich). Insulin receptor, IGF1 receptor and AKT (thr308) phosphorylation, as a percentage of total protein, was determined using MesoScale Discovery phospho and total protein assays, performed according to the manufacturer's instructions and detected on the SECTOR Imager 6000 (MesoScale Discovery).
Glucose uptake assays
Glucose uptake in primary human myotubes was quantified using either a radiometric or a fluorometric assay. For the radiometric assay, obese myotubes were cultured in 6-well plates and either left unstimulated or were pre-incubated for 24 h with vaspin (100 ng/mL). The next day myotubes were washed twice in warm PBS and incubated in serum-free media (Ham's F10) for 2 h. Myotubes were washed a further two times before incubation with 2 mL reaction buffer (138 mM NaCl, 1.85 mM CaCl 2 , 1.3 mM MgSO 4 , 4.8 mM KCl, 50 mM HEPES, pH 7.4, 0.2% (W/V) BSA) for 45 min at 37°C. Myotubes were then incubated with or without insulin (100 nM) for 30 min on a plate warmer at 37°C before the addition of 250 µL of 27.8 kBq [ 3 H]-2-DOG and 10 µM 2-DOG at timed intervals to each well for 15 min. The buffer was aspirated with a vacuum pump and myotubes were washed three times with ice cold PBS containing 10 mM glucose. Myotubes were then lysed in 500 µL 0.5 M NaOH and 0.1% SDS then transferred to scintillation vials and 5 mL liquid scintillation fluid was added. Samples were vortexed and assayed for [ 3 H]-2-DOG uptake expressed as disintegrations/min/well using a β-counter.
For the fluorometric assay, lean and obese myotubes cultured in 96-well plates were washed three times in PBS before incubation with glucose-free DMEM media (Gibco) for 3 h. Myotubes were washed a further three times before incubation with 100 µM 2-NBDG glucose (Sigma), diluted in glucose-free media with or without 100 nM insulin, for 30 min. Myotubes were subject to a further three washes with PBS before final addition of 100 µL PBS/well. Fluorescence was measured by excitation at 485 nm and emission at 528 nm using a Synergy 2 Multi-Detection Microplate Reader (BioTek). Untreated myotubes were included to correct for myotube auto-fluorescence. Five biological replicates were performed per condition for each cell line.
Quantification of GLUT4 translocation by flow cytometry
Quantification of GLUT4 translocation to the cell membrane was determined by flow cytometry in myoblasts as previously described (Koshy et al. 2010) . In brief, primary human myoblasts (10 5 cells/condition) from obese subjects (n = 5) were treated with either vaspin (100 ng/mL, 15 min) or insulin (100 nM, 15 min). Post-treatment, cells were washed with PBS and stained for GLUT4 (Anti-GLUT4 antibody ab65267, Abcam. 0.05 µg/10 5 cells, diluted in 2% BSA PBS) on ice for 20 min. A second wash with PBS was then preformed, 
Results
The expression of vaspin and its putative receptor GRP78 are increased in the skeletal muscle and SAT of obese individuals
We first examined the mRNA expression of vaspin and its putative plasma membrane receptor GRP78 (HSPA5) in both skeletal muscle and SAT in humans of varying BMI. Vaspin mRNA expression was significantly greater in both SAT (2.5-fold, P < 0.01) and skeletal muscle (1.5-fold, P < 0.05) of obese subjects in comparison to lean subjects ( Fig. 1A and B) and demonstrated a significant positive correlation with BMI ( Fig. 1E ) and skeletal muscle (Fig. 1F) . Similarly, expression of GRP78 was significantly greater in both SAT (1.5-fold, P < 0.05) and skeletal muscle (1.8-fold, P < 0.05) of obese subjects in comparison to lean subjects ( Fig. 1C and D) and was positively correlated with BMI in both tissue types ( Fig. 1G and H) .
Vaspin is rapidly secreted from human adipose tissue and muscle tissue and is detectable systemically in both lean and obese individuals
To investigate the potential for vaspin to signal between human SAT and skeletal muscle we first examined by immunoblotting the ex vivo secretion of vaspin from SAT and skeletal muscle into culture media over a 24 h time course. Vaspin was detected in serum-free culture media that had been conditioned with either SAT or skeletal muscle for 1 h, indicating that vaspin is rapidly secreted from both tissue types. The amount of vaspin detected in both SAT and skeletal muscle-conditioned media increased up to 6 h and was maintained for the duration of 24 h ( Fig. 2A and B) . Further, a significantly greater level of vaspin was detected in SAT conditioned media of obese (n = 16) in comparison to lean (n = 17) at 24 h (Fig. 2C) . We then examined by ELISA whether vaspin could be detected systemically in human sera, and whether there was a difference in the systemic concentration of vaspin
Figure 2
Vaspin is rapidly secreted from human subcutaneous adipose tissue and systemically is elevated in obese individuals. Detection of vaspin protein in (A) SAT conditioned media and (B) skeletal muscle-conditioned media in lean and obese subjects over a 24 h time course, as measured by immunoblotting. 10 µL adipose or skeletal muscle-conditioned media was loaded per sample lane. Bars represent mean densitometric units ± s.e.m. of immunblots from n = 3 subjects analysis. *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from time = 0 media control sample as determined by one-way ANOVA with Dunnett's post-hoc tests. (C) Densitometric analysis of vaspin protein expression in adipose conditioned media at 24 h from lean (n = 17) and obese (n = 16) subjects as measured by immunoblotting. 10 µL of adipose conditioned media was loaded per sample lane. between lean (n = 16) and obese (n = 15) individuals. Vaspin was detected in the serum of both lean and obese individuals but there was no significant difference between levels found in obese individuals in comparison to lean individuals in either males or females (Fig. 2D) . However, serum vaspin was on average higher in obese females compared to lean females. Furthermore, although there was no significant correlation between between serum vaspin and BMI in males (Fig. 2E) , in females we found a significant positive correlation (R 2 = 0.267, P < 0.05) with BMI (Fig. 2F) .
The effect of vaspin on insulin signalling pathways in primary human myotubes
We next examined the effect of stimulating primary human myotubes ( Fig. 3A) with recombinant human vaspin on insulin signalling pathways. First, lean primary myotubes were stimulated with recombinant vaspin (100 ng/mL) acutely for either 5, 10 or 15 min and AKT activity (phosphorylation) quantified using MesoScale immunoassays (MesoScale Discovery). Myotubes stimulated with vaspin for either 10 or 15 min showed a significant threefold increase in phosphoAKT (threonine 308 )/total AKT expression (Fig. 3B ), which along with activation of the other AKT phosphorylation site (serine 473 ) was validated by immunoblotting (n = 4 patient replicates) (Fig. 3C, D and E) . To investigate the mechanism of the vaspin-mediated induction in basal AKT activity we examined whether acute or chronic stimulation of human myotubes with vaspin led to activation of either the insulin receptor or the IGF receptor. As expected, 15 min of insulin stimulation alone induced a significant increase in the phosphorylation of both the insulin receptor and the IGF receptor ( Fig. 3F and G). However, stimulation of myotubes with vaspin for either 15 min or chronic stimulation for 24 h induced no phosphorylation of either the insulin receptor or the IGF receptor ( Fig. 3F and G) , indicating that vaspin did not directly affect activation of upstream insulin signalling. Given these findings, we then examined whether vaspin affected the activity of downstream insulin signalling by determining the activity status of PI3K by immunoblotting. Acute stimulation of primary human myotubes (n = 4 patients) with vaspin (100 ng/mL) induced a transient increase in phosphorylation of PI3K between 10 and 15 min as determined by immunoblotting ( Fig. 3H and I) .
Vaspin induces the expression and translocation of GLUT4 protein and promotes glucose uptake in the presence of insulin in human myotubes
Following these data, and with the observation that vaspininduced activation of downstream insulin signalling components, we then investigated the functional metabolic role of vaspin by examining whether vaspin affected GLUT4 expression and glucose uptake in primary human myoblasts and myotubes from obese subjects.
First, we examined whether there was a difference in skeletal muscle GLUT4 mRNA expression between old obese (n = 8), old lean (n = 8) and young (n = 7) subjects. Compared to young subjects, GLUT4 expression was 69% lower in the skeletal muscles from old obese subjects (P < 0.05; Fig. 4A ). In line with the relatively low expression of GLUT4 in old obese muscle, myotubes derived from old obese subjects also displayed a blunted glucose uptake response to insulin (100 nM, 30 min), in comparison to myotubes cultured from old lean subjects (Fig. 4B) .
Stimulation of obese myotubes with vaspin (100 ng/mL) for 24 h induced a significant (P < 0.05) ~fivefold increase in the expression of GLUT4 mRNA (Fig. 4C) , which translated into a significant (P < 0.05) increase in GLUT4 protein (Fig. 4D) . Furthermore, stimulation of primary human myoblasts with either insulin (100 nM) or vaspin (100 ng/mL) for 15 min caused a significant (P < 0.05) increase in GLUT4 protein surface expression, compared to non-stimulated myoblasts, indicative of an increase in GLUT4 protein translocation (Fig. 4E) .
We then investigated whether these vaspin-mediated effects on both the expression and translocation of GLUT4 were sufficient to impact on glucose uptake in previously insulin-insensitive obese myotubes. Primary human myotubes from old obese subjects that had not been pretreated with vaspin showed no increase in glucose uptake in response to 30 min of insulin stimulation (100 nM), compared to unstimulated control (Fig. 4F) . However, 30 min insulin stimulation significantly increased glucose uptake in vaspin pre-treated myotubes, compared to control myotubes (Fig. 4F) . Finally, since p38 and AMPK activation have been implicated in promoting GLUT4 expression we examined the effect of vaspin stimulation on their activation status. Acute stimulation of primary human myotubes (0-15 min) with 100 ng/mL vaspin induced a significant activation of both p38 (n = 4 biological replicates) and AMPK (n = 4 biological replicates), as measured by immunoblotting (Fig. 4G, H and I ). Vaspin and muscle insulin sensitivity T Nicholson et al. 241:1
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Discussion
With the current dearth of human data on the adipokine vaspin, this study is the first to characterise the expression of vaspin in both skeletal muscle and adipose tissue in elderly individuals of varying BMI and to report the functional effect of vaspin on human skeletal muscle insulin signalling pathways and glucose uptake. Previously, vaspin mRNA has been reported to be detectable in only around 15% of human SAT samples, with no expression reported in SAT of lean subjects (Kloting et al. 2006) . In the present study, we detected vaspin mRNA in both SAT and skeletal muscle from both lean and obese individuals. However, vaspin was more highly expressed in the SAT and skeletal muscles from obese individuals and in both tissue types its expression positively correlated with BMI. We also found that vaspin protein was rapidly secreted from both human SAT and skeletal muscle tissue, with the quantity secreted from obese tissues being greater than from lean tissues. Together these data support the findings from rodent studies that describe an increase in vaspin tissue expression with obesity (Hida et al. 2000 , Heiker et al. 2013 . It is important to note that our finding that vaspin expression in adipose and muscle tissue was increased with obesity was in patients without type 2 diabetes. Gene array data in the GEO database does not reveal any significant difference in vaspin adipose tissue expression between patients with or without insulin resistance or in those with type 2 diabetes compared to individuals with normal glucose tolerance (Edgar et al. 2002) . Furthermore, a recent report found that circulatory levels of vaspin in morbidly obese individuals declined following weight loss induced by laparoscopic SAT of these individuals. This might suggest that elevated secretion of vaspin from SAT in obese individuals is more likely to have localised effects rather than systemic effects on distal tissues. However, it should be noted that serum concentrations of vaspin were variable and therefore with a larger cohort the higher on average concentration of vaspin in obese individuals may have reached statistical significance.
A number of previous publications have examined systemic levels of vaspin in males and females of varying BMI, with contrasting results. In individuals aged 17-79 it was found that serum vaspin was significantly higher in obese male subjects compared to lean male subjects, but was not significantly different between obese and lean females (Youn et al. 2008) . However, the study by Esteghamati et al. found that serum vaspin levels positively correlated with BMI in both males and females (Esteghamati et al. 2014 ). In addition, higher levels of serum vaspin were reported in females compared to males in individuals with normal glucose tolerance, but no gender difference was seen in individuals with type 2 diabetes (Youn et al. 2008) . However, Seeger et al. examined serum vaspin levels in diabetic and non-diabetic patients in both controls and in those patients on chronic haemodialysis (CD) with BMI between 26 and 30 and found that vaspin was higher in females and furthermore that gender was an independent predictor of circulating vaspin concentrations (Seeger et al. 2008) . Together these observations could reflect sex dimorphism in SAT distribution and quantity (Fuente-Martin et al. 2013 , White & Tchoukalova 2014 . It is known for example that females predominantly accumulate more SAT than males (Kotani et al. 1994) , and thus vaspin may play a greater role in mediating glucose homeostasis in females than in males. Indeed, some studies have previously reported that the prevalence of metabolic syndrome is higher in females than in males (Beigh & Jain 2012) , with central adiposity being a greater risk factor for metabolic diseases in females (Li et al. 2006 , Holliday et al. 2011 .
Contrary to the above studies, we found no significant difference between serum vaspin concentration between males and females in either normal weight or obese individuals. Furthermore, and contrary to the findings of Esteghamati et al. (2014) we did not find a significant correlation between BMI and vaspin levels in males. However, we did observe that serum vaspin in females significantly correlated with BMI. These disparities may be a reflection of the relatively smaller sample size used in our study but also likely reflects differences between subject cohorts. For example, the male subjects studied by Youn et al. (2008) had a mean age of 39 years, whilst both the male and female subjects studied by Esteghamati et al. (2014) had a mean age of 49 years, considerably lower than the mean age of subjects in this study.
Vaspin-mediated activation of PI3K/AKT has been reported previously in several other cell types, including pancreatic cells (Liu et al. 2017) , 3T3-L1 preadipocytes (Liu et al. 2015) and endothelial progenitor cells . Furthermore, it was recently reported that vaspin promotes the PI3K/AKT signalling pathway leading to increased GLUT4 protein expression in rats fed a high-fat diet (Liu et al. 2018) and can improve glucose tolerance in mice . Therefore, our demonstration that vaspin induces activation of PI3K-AKT signalling and increases insulin sensitivity in obese human myotubes is significant. These vaspin-induced effects appear to occur independently of upstream insulin signalling, since vaspin had no direct effect on either the insulin receptor or IGF-1 receptor phosphorylation status. Activation of PI3K/AKT signalling is known to promote GLUT4 translocation and glucose uptake in skeletal muscle cells (Dugani & Klip 2005) , and here we report that vaspin promotes GLUT4 expression and translocation and facilitates glucose uptake in human obese myotubes. Notably, 15 min stimulation of primary human myoblasts derived from obese subjects with vaspin was able to significantly increase GLUT4 surface translocation to a similar magnitude to that observed with insulin stimulation. This finding may be of clinical significance given that GLUT4 translocation is impaired in type 2 diabetes patients with insulin insensitivity (Maria et al. 2015) . Indeed, since our data shows that vaspin induces insulin signalling independent of activating the insulin receptor this could provide a novel route to therapeutically improve glucose maintenance in insulinresistant individuals.
Despite being able to promote GLUT4 translocation we found that insulin stimulation of obese myotubes did not result in glucose uptake. Previous studies in rats have demonstrated that GLUT4 expression declines with age (dos Santos et al. 2012 ) and obesity (Kahn & Pedersen 1993 ). Here we report for the first time in humans that muscle tissue derived from elderly obese individuals displayed a significantly lower expression of GLUT4 mRNA in comparison to young lean individuals. The retention of this phenotype in primary human myotubes from elderly obese subjects may therefore explain the blunted insulin response observed at baseline.
Importantly, prolonged 24 h pre-treatment of obese myotubes with vaspin sensitised them to insulin-mediated glucose uptake. This sensitisation is likely due to vaspin increasing the bioavailable intracellular pool of GLUT4. Previous studies in 3-T3-L1 adipocytes (Liu et al. 2015) and in mice (Hida et al. 2005) have reported that vaspin induces GLUT4 expression. Here, we report for the first time that vaspin significantly induces GLUT4 mRNA and GLUT4 protein expression in human skeletal muscle. Importantly, we also demonstrate that vaspin is able to activate both AMPK and p38 signalling in primary human myotubes. AMPK activation has previously been reported to upregulate GLUT4 expression in primary human myotubes (McGee et al. 2008) , while p38 is known to regulate transcription factors that control the expression of GLUT4 (Niu et al. 2003 , Montessuit et al. 2004 . Activation of these signalling pathways may therefore be a potential mechanism to explain the vaspin-induced upregulation in GLUT4 mRNA and protein expression observed.
However, it should be noted that primary human myotubes in culture elicit relatively low insulin-stimulated glucose uptake (Montell et al. 2001 , Al-Khalili et al. 2003 , Aas et al. 2004 ), compared to skeletal muscle tissue. This could be due to low basal expression of GLUT4, which has been attributed to denervation (Chowdhury et al. 2005 , Jensen et al. 2009 ) and the subsequent absence of contraction. Therefore, in our model system, treatment of myotubes with vaspin may only be increasing the pool of bioavailable GLUT4 towards physiological levels. Whether vaspin administration in humans in vivo would have the same effect remains to be seen.
A cell surface receptor for vaspin has yet to be fully elucidated. One possible mechanism is that vaspin signals through GRP78, a protein that has an important intracellular regulatory role during cellular ER stress (Lee 2005 , Matsuo et al. 2013 . However, recent evidence shows GRP78 also functions as a cell surface receptor, with membrane localised GRP78 binding vaspin and in turn promoting AKT and AMPK signalling in H-4-II-E-C3 cells . Here, we show GRP78 expression is present in both SAT and skeletal muscle in older individuals. Expression of GRP78 was found to be significantly greater in both SAT and skeletal muscle of obese subjects and displayed a positive correlation with BMI in each case. This is concurrent with the results of Khadir et al. , who also found increased GRP78 expression in SAT of obese humans (Khadir et al. 2016) . Chronic ER stress can be induced by obesity (Yilmaz 2017) and is associated with inflammatory adipose tissue (Kawasaki et al. 2012) , and this may explain the increased GRP78 expression in muscle and adipose tissue of obese individuals in our present study. Additionally, ER stress has been shown to promote re-localisation of GRP78 to the cell membrane, thus increasing ligand-binding capacity (Zhang et al. 2010) . Whether the functional effects of vaspin we report here in human myotubes are dependent on GRP78 signalling requires further study.
In summary, this study shows that vaspin is directly secreted from both human SAT and skeletal muscle and its expression is increased with increasing adiposity in older people. Functionally, vaspin induces PI3K/AKT activation, increases both GLUT4 expression and translocation and promotes insulin-stimulated glucose uptake in primary obese older human myotubes. This data support a role for vaspin as a protective adipokine in the development of insulin resistance in elderly obese individuals. Further studies are needed to identify the mechanism of action of vaspin as this may provide a novel therapeutic target to improve insulin sensitivity independent of the insulin receptor.
